AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting riskPopularity #3,816

MDCX · NASDAQ · Biotechnology

Medicus Pharma (MDCX)

Develops clinical-stage therapies for skin cancer, urology, oncology, and women’s health.

$0.1651

vs last close−0.01 (−3.45%)

Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
Proactive Investors23h ago
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
GlobeNewsWireSep 21
Wall Street sets positive tone as investors digest hotter inflation data
Proactive Investors - FinanceSep 11
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Proactive InvestorsSep 10Clinical
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs
Proactive InvestorsSep 8
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
GlobeNewsWireSep 8Operations
Medicus Pharma advances pipeline during Q2 with key milestones
Proactive InvestorsAug 13
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
AccesswireAug 12
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Proactive InvestorsAug 3
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
GlobeNewsWireAug 3
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Proactive InvestorsAug 1
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Proactive Investors - FinanceAug 1
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Proactive InvestorsJul 31
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
GlobeNewsWireJul 31
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Proactive Investors - FinanceJul 31
Honeywell upgraded by Bank of America on stronger order trends
Proactive Investors - FinanceJul 28
Medicus Pharma receives FDA clearance to begin registrational SkinJect study for Gorlin syndrome
Proactive InvestorsJul 27
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
GlobeNewsWireJul 27
Nvidia in talks to back OpenAI data center financing with $250B guarantee, WSJ reports
Proactive Investors - FinanceJul 27
Medicus Pharma CEO details Teverelix progress – ICYMI
Proactive InvestorsJul 18